• LAST PRICE
    7.4000
  • TODAY'S CHANGE (%)
    Trending Down-0.1700 (-2.2457%)
  • Bid / Lots
    7.3900/ 5
  • Ask / Lots
    7.4100/ 6
  • Open / Previous Close
    7.4900 / 7.5700
  • Day Range
    Low 7.2100
    High 7.5900
  • 52 Week Range
    Low 2.1800
    High 13.6800
  • Volume
    404,817
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 7.57
TimeVolumeLRMR
09:32 ET37547.49
09:35 ET32067.49
09:37 ET30617.515
09:39 ET14347.515
09:42 ET19507.53
09:44 ET16817.555
09:46 ET10127.55
09:48 ET60437.43
09:50 ET21777.425
09:51 ET17067.425
09:53 ET12007.38
09:55 ET32247.42
09:57 ET14887.52
10:00 ET18817.51
10:02 ET33427.405
10:04 ET21717.455
10:06 ET10007.46
10:08 ET13407.49
10:09 ET19937.475
10:11 ET27757.47
10:13 ET29287.43
10:15 ET10957.455
10:18 ET23147.45
10:20 ET16857.45
10:22 ET22237.45
10:24 ET13597.45
10:26 ET12207.465
10:27 ET23037.455
10:29 ET32697.42
10:31 ET44057.435
10:33 ET23137.41
10:36 ET140597.295
10:38 ET20707.295
10:40 ET16607.315
10:42 ET24657.31
10:44 ET101927.305
10:45 ET31417.3228
10:47 ET23177.38
10:49 ET11587.38
10:51 ET14467.365
10:54 ET19967.38
10:56 ET20257.375
10:58 ET14977.375
11:00 ET60847.3801
11:02 ET96397.34
11:03 ET24887.32
11:05 ET12987.355
11:07 ET26807.4
11:09 ET12657.47
11:12 ET9577.47
11:14 ET21557.47
11:16 ET22007.44
11:18 ET16457.44
11:20 ET18517.42
11:21 ET7997.415
11:23 ET9507.425
11:25 ET15467.47
11:27 ET10597.49
11:30 ET7877.49
11:32 ET14897.48
11:34 ET26797.5
11:36 ET24857.55
11:38 ET13507.54
11:39 ET8687.525
11:41 ET15287.525
11:43 ET27297.46
11:45 ET18977.45
11:48 ET14337.45
11:50 ET8957.455
11:52 ET26007.46
11:54 ET6447.46
11:56 ET9657.465
11:57 ET14137.45
11:59 ET34157.3748
12:01 ET11907.35
12:03 ET7217.36
12:06 ET27287.35
12:08 ET2577.34
12:10 ET17717.34
12:12 ET27237.315
12:14 ET13767.33
12:15 ET10487.3
12:17 ET11037.325
12:19 ET7427.36
12:21 ET6007.345
12:24 ET6007.36
12:26 ET36157.335
12:28 ET7547.335
12:30 ET12737.32
12:32 ET20767.33
12:33 ET14757.34
12:35 ET16837.315
12:37 ET9007.33
12:39 ET7817.33
12:42 ET12527.31
12:44 ET10007.325
12:46 ET35527.305
12:48 ET9707.3
12:50 ET16957.28
12:51 ET6327.28
12:53 ET13747.29
12:55 ET13777.27
12:57 ET39957.27
01:00 ET53607.29
01:02 ET9007.28
01:04 ET11447.28
01:06 ET9047.27
01:08 ET25297.27
01:09 ET18297.26
01:11 ET14197.25
01:13 ET8427.25
01:15 ET14857.26
01:18 ET17257.27
01:20 ET10907.28
01:22 ET10997.28
01:24 ET25967.265
01:26 ET9737.23
01:27 ET11447.225
01:29 ET60157.245
01:31 ET42027.22
01:33 ET17097.24
01:36 ET16647.23
01:38 ET12377.24
01:40 ET38707.28
01:42 ET40217.28
01:44 ET12737.29
01:45 ET10717.29
01:47 ET7397.31
01:49 ET30847.3
01:51 ET12277.29
01:54 ET15207.33
01:56 ET11807.36
01:58 ET11147.37
02:00 ET6007.39
02:02 ET7507.4
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLRMR
Larimar Therapeutics Inc
483.0M
-6.4x
---
United StatesALT
Altimmune Inc
482.6M
-4.2x
---
United StatesPRME
Prime Medicine Inc
475.3M
-1.9x
---
United StatesTHRD
Third Harmonic Bio Inc
497.5M
-15.1x
---
United StatesKALV
Kalvista Pharmaceuticals Inc
502.6M
-3.2x
---
United StatesAURA
Aura Biosciences Inc
504.5M
-5.7x
---
As of 2024-11-05

Company Information

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Contact Information

Headquarters
THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
Phone
617-622-4003
Fax
302-655-5049

Executives

Independent Chairman of the Board
Joseph Truitt
President, Chief Executive Officer, Director
Carole Ben-Maimon
Chief Financial Officer, Secretary
Michael Celano
Chief Medical Officer
Russell Clayton
Chief Development Officer
Gopi Shankar

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$483.0M
Revenue (TTM)
$0.00
Shares Outstanding
63.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.95
EPS
$-1.15
Book Value
$1.86
P/E Ratio
-6.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.